Phathom Pharmaceuticals I... (PHAT)
| Bid | 6.1 |
| Market Cap | 447.42M |
| Revenue (ttm) | 54.16M |
| Net Income (ttm) | -327.7M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -1.21 |
| Forward PE | -1.75 |
| Analyst | Buy |
| Ask | 6.4 |
| Volume | 662,379 |
| Avg. Volume (20D) | 1,126,544 |
| Open | 6.52 |
| Previous Close | 6.55 |
| Day's Range | 6.17 - 6.52 |
| 52-Week Range | 4.07 - 19.71 |
| Beta | 0.64 |
About PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re...
Analyst Forecast
According to 4 analyst ratings, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 304.67% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call TranscriptPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...
